miRNA-96 might serve as potential biomarkers for cervical cancer

Date 24 November 2018
Event ESMO Asia 2018 Congress
Session Poster display - Cocktail
Topics Cervical Cancer
Translational Research
Presenter Jiao-Mei Gong
Citation Annals of Oncology (2018) 29 (suppl_9): ix79-ix86. 10.1093/annonc/mdy436
Authors J. Gong
  • Clinical Laboratory, Second Affiliated Hospital of Zhengzhou University, 450014 - Zhengzhou/CN

Abstract

Background

Cervical cancer is the second most common cancer in women around the world, followed by breast cancer, and remains to be a major health care problem in developing countries. MicroRNAs are a class of small non-coding RNAs which regulate posttranscriptionally the gene expression, thereby it is implicated in a wide range of biological processes including cellular proliferation, differentiation, and apoptosis.

Methods

Real-time quantitative polymerase chain reaction technology was used to detect the expression of miRNA-96 in 122 cervical cancer tissues, 96 cervical intraepithelial neoplasia (CIN) tissues and 84 normal tissues. The associations of miRNA-96 expression with clinicopathologic variables were analyzed. Kaplan-Meier survival analysis was performed to analyze the association of miRNA-96 expression with overall survival (OS) of patients.

Results

The expression level of miRNA-96 in cervical cancer tissues was higher than that in CIN tissues and normal cervical tissues. These were significant differences (P < 0.05). The expression level of miRNA-96 in CIN tissues was also higher than that in normal cervical tissues. The expression level of miRNA-96 in cervical cancer tissues was significantly associated with histological grade (P < 0.05), FIGO stage (P < 0.05), and lymph node metastasis (P < 0.05). Kaplan-Meier analysis showed that the survival rate of patients with higher miRNA-96 levels was significantly lower than that of patients with lower miRNA-96 expression levels.

Conclusions

The miRNA-96 might serve as potential biomarkers for cervical cancer.

Editorial acknowledgement

Clinical trial identification

Legal entity responsible for the study

Second Affiliated Hospital of Zhengzhou University.

Funding

Scientific and Technological Research of Henan Province (182102311236).

Disclosure

The author has declared no conflicts of interest.